The monitoring of serum autoantibodies in patients is an important tool for addressing many needs, from drug development to clinical trials. Different study designs enable the development of biomarker panels for addressing the following applications:
Using the Patient Selection approach discussed above, pharmaceutical companies are now able to revitalize stalled drug programs. Some drugs encounter regulatory hurdles that could be overcome... More
Antibodies are well suited to non-invasive diagnostic applications. Since they are produced in abundance relative to diseased tissue, they give earlier warning of disease than other biomarker classes which can take time to accumulate to detectable levels... More
For more information on using this technology, click here.